ClinicalTrials.gg

Program

rilzabrutinib

Also written as “Rilzabrutinib”, “rilzabrutinib SAR444671” and “Rilzabrutinib dose 1”.

Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Anemia, Hemolytic, Autoimmune · Immunoglobulin G4-Related Disease · Pemphigus · Common Variable Immunodeficiency, led by Sanofi.

Furthest: phase 3, since Nov 29, 201823 company-led studies, 11 open or runningNext primary completion: Nov 25, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi2311 open or runningphase 3since Nov 29, 2018Feb 24, 2016Nov 25, 2026phase 3 · NCT07216079

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Feb 24, 2016.

  1. Feb 3, 2021Phase 1 study in Healthy VolunteersNCT04748926 · 24 enrolled · Australia
  2. Aug 5, 20212 phase 2 studiesNCT05002777, NCT05018806
  3. Oct 17, 20212 phase 2 studiesNCT05104892, NCT05107115
  4. Mar 18, 2024Phase 1 study in Autoimmune DiseasesNCT06342700 · 28 enrolled · United States
  5. May 30, 20242 phase 1 studiesNCT06444204, NCT06444191
  6. Jul 8, 2024Phase 2 study in Glomerulosclerosis, Focal SegmentalNCT06500702 · 84 planned · United States, Argentina, Australia and more
  7. May 8, 20252 phase 3 studiesNCT06975865, NCT07007962
  8. May 14, 2025Phase 2 study in Graves DiseaseNCT06984627 · 30 planned · Argentina, Canada, Chile and more
  9. Jul 17, 2025Phase 3 study in Anemia, Hemolytic, AutoimmuneNCT07086976 · 90 planned · United States, Argentina, Austria and more
  10. Sep 17, 2025Phase 3 study in Immunoglobulin G4-Related DiseaseNCT07190196 · 124 planned · United States, Argentina, Belgium and more
  11. Oct 9, 2025Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT07216079 · 3 enrolled · Japan
  12. Sep 21, 20262 phase 1 studiesNCT07855250, NCT07853131
  13. Oct 1, 2026Primary completion moved from 2026-08-25 to 2027-02-11Date moved laterphase 2 · +6 months · NCT06984627
  14. Oct 28, 2026Phase 3 study in Common Variable ImmunodeficiencyNCT07923305 · 96 planned

Ahead

  1. Nov 3, 2026Primary completion: phase 1 study in Healthy VolunteerNCT07855250
  2. Nov 25, 2026Primary completion: phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT07216079
  3. Dec 23, 2026Primary completion: phase 2 study in Glomerulosclerosis, Focal SegmentalNCT06500702
  4. Feb 11, 2027Primary completion: phase 2 study in Graves DiseaseNCT06984627

TargetBeta

BTK →read by rule
“An orally bioavailable reversible covalent inhibitor of Bruton's tyrosine kinase (BTK), ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

All 23 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07923305Common Variable Immunodeficiency3Not yet recruitingMay 10, 203596
NCT07853131Renal Insufficiency · United States1RecruitingApr 21, 202716
NCT07855250Healthy Volunteer · Canada1Active, not recruitingNov 3, 202614
NCT07216079Purpura, Thrombocytopenic, Idiopathic · Japan3Active, not recruitingNov 25, 20263
NCT07190196Immunoglobulin G4-Related Disease · United States, Argentina, Belgium and more3RecruitingJun 28, 2028124
NCT07086976Anemia, Hemolytic, Autoimmune · United States, Argentina, Austria and more3RecruitingMay 31, 202890
NCT07007962Purpura, Thrombocytopenic, Idiopathic · United States, Austria, Czechia and more3RecruitingNov 5, 202760
NCT06984627Graves Disease · Argentina, Canada, Chile and more2RecruitingFeb 11, 202730
NCT06975865Anemia, Sickle Cell · United States, Belgium, Brazil and more3RecruitingJul 23, 2027192
NCT06500702Glomerulosclerosis, Focal Segmental · United States, Argentina, Australia and more2RecruitingDec 23, 202684
NCT06444204Liver Diseases · United States1CompletedMar 23, 202129
NCT06444191Healthy Volunteers · United States1CompletedApr 12, 202123
NCT06342700Autoimmune Diseases · United States1CompletedApr 23, 202428
NCT05107115Chronic Urticaria · Argentina, Canada, Chile and more2CompletedJul 19, 2023160
NCT05104892Asthma · Argentina, Bulgaria, Canada and more2CompletedFeb 6, 2024196
NCT05018806Dermatitis, Atopic · United States, Canada, Chile and more2CompletedJun 23, 2023124
NCT05002777Warm Autoimmune Hemolytic Anemia (wAIHA) · United States, Austria, China and more2Active, not recruitingMay 23, 202422
NCT04748926Healthy Volunteers · Australia1CompletedMay 21, 202124
NCT04562766Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more3CompletedJan 15, 2025232
NCT04520451Immunoglobulin G4-Related Disease · United States, Canada, France and more2CompletedOct 15, 202427
NCT03762265Pemphigus · United States, Argentina, Australia and more3TerminatedJul 30, 2021131
NCT03395210Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Bulgaria and more2CompletedJan 31, 202386
NCT02704429Pemphigus · Australia, Croatia, France and more2CompletedDec 18, 201942

How it is read

Names in the registry

  • “Rilzabrutinib”, 10 entries
  • “rilzabrutinib”, 9 entries
  • “rilzabrutinib SAR444671”, 3 entries
  • “Rilzabrutinib dose 1”, 1 entry
  • “Rilzabrutinib dose 2”, 1 entry

Codes read as this program: SAR444671.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.